| DB ID | MyCo_1104 |
| Title | (1→3)-β-d-Glucan in Cerebrospinal Fluid as a Biomarker for Candida and Aspergillus Infections of the Central Nervous System in Pediatric Patients |
| Year | 2015 |
| PMID | 26407252 |
| Fungal Diseases involved | Candida infection |
| Associated Medical Condition | None |
| Genus | Candida |
| Species | albicans |
| Organism | Candida albicans |
| Ethical Statement | The clinical study protocol for data collection was reviewed and approved by each in- stitution’s institutional review board, New York-Presbyterian Hospital, Weill Cornell Medical College, New York, Miller Children's and Women's Hospital Long Beach., Weill Cornell Medical Center of Cornell University, New York. |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | USA |
| Cohort | Here conducted a multicenter retrospective study that in- cluded chart reviews of pediatric subjects, aged birth to 18 years, who had neurologic symptoms, who had a work- ing diagnosis of HCME or ACNS, and whose CSF was evaluated for the detection of (1!3)-β-D-glucan. |
| Cohort No. | 9 |
| Age Group | 0–18 |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | Assay |
| Analysis Method | BDG Assay -Beacon Diagnostics Laboratory (Associates of Cape Cod, Inc., East Falmouth, MA). |
| ELISA kits | None |
| Assay Data | BDG Assay -Beacon Diagnostics Laboratory (Associates of Cape Cod, Inc., East Falmouth, MA). |
| Validation Techniques used | BDG Assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
